Results 1 to 10 of about 33,669 (192)

Multidisciplinary Approach for Dental Management of Congenital Insensitivity to Pain with Anhidrosis: Clinical Case Report with 12-Month Follow-Up [PDF]

Dentistry Journal
Background: Congenital Insensitivity to Pain and Anhidrosis (CIPA) is a rare autosomal recessive disorder characterized by congenital analgesia, anhidrosis, and multisystem involvement affecting the musculoskeletal, cutaneous, oral, and para-oral ...
Almoataz B. A. T. Abdel-bari, Mohamed Fawzy, Khaled A. Saad, Hatem A. Alhadainy   +3 more
doaj   +2 more sources

Prognostic value of the CIPA nutritional screening tool in over 30,000 hospitalized patients: a retrospective study (2014–2022) [PDF]

Frontiers in Nutrition
IntroductionMalnutrition is a well-established negative prognostic factor in hospitalized patients, contributing to increased morbidity and mortality. The CIPA (Control of Food Intake, Protein, and Anthropometry) screening tool was developed to identify ...
Javier García Fernández, José Pablo Suárez-Llanos, Cristina Lorenzo González, Elena Márquez Mesa, María Araceli García Núñez, Maria Demelza Farrais Luis, Manuel Enrique Fuentes Ferrer   +6 more
doaj   +2 more sources

Ocular Manifestations in Congenital Insensitivity to Pain with Anhidrosis: A Window into a Rare Syndrome [PDF]

Vision
Background: Congenital insensitivity to pain with anhidrosis (CIPA) is a rare autosomal recessive syndrome caused by loss-of-function mutations in the Neurotrophic Tyrosine Kinase Receptor 1 gene, characterized by recurrent episodes of infections and ...
Mohammed Baker, Kenda Abedal-Kareem, Sadeen Eid, Mahmoud Alkhawaldeh, Yahya Albashaireh, Jihan Joulani, Sara Bani Amer, Ethar Hazaimeh, Omar F. Jbarah, Abdelwahab Aleshawi, Rami Al-Dwairi   +10 more
doaj   +2 more sources

CIPA - Heritage Documentation: 50 Years: Looking Backwards [PDF]

The International Archives of the Photogrammetry, Remote Sensing and Spatial Information Sciences, 2019
The ICOMOS-ISPRS Scientific Committee, CIPA-Heritage Documentation is proud to present this publication in the occasion of its 50th birthday.Our intention with this publication is to look backwards at the achievements of CIPA while at the same time to ...
E. Stylianidis
doaj   +3 more sources

Uncovering oral and maxillofacial clues in congenital insensitivity to pain with anhidrosis: what can sibling cases teach us? [PDF]

BMC Oral Health
Background Congenital Insensitivity to Pain with Anhidrosis (CIPA) is an extremely rare congenital disorder characterized by severe clinical and oral manifestations.
Katibe Tugce Temur
doaj   +2 more sources

Ultrasound-guided femoral nerve block combined with lateral femoral cutaneous nerve block in a patient with congenital insensitivity to pain and anhidrosis: a case report [PDF]

BMC Anesthesiology
Congenital insensitivity to pain with anhidrosis (CIPA), also known as hereditary sensory and autonomic neuropathies (HSAN I-V), is an exceptionally rare autosomal recessive disorder. The pathogenesis of CIPA remains not fully elucidated.
Jianzhong Li, Mingming Zhang, Dalong Dong, Hong Xu, Ankui Wang, Qi Liu, Lei Duan   +6 more
doaj   +2 more sources

Raising awareness through a case of recurrent fractures in a child with congenital insensitivity to pain and anhidrosis in Saudi Arabia [PDF]

The Ewha Medical Journal
Patients with congenital insensitivity to pain and anhidrosis (CIPA) exhibit an inability to perceive pain, recurrent fractures, self-mutilation, and impaired thermoregulation, which lead to severe complications and high morbidity.
Amaal Aldosari, Abdulraheem Almokhtar, Hashem Bukhary, Raed Sharaf, Khalid Alhomayani   +4 more
doaj   +2 more sources

Uncertainty Quantification Reveals the Importance of Data Variability and Experimental Design Considerations for in Silico Proarrhythmia Risk Assessment [PDF]

Frontiers in Physiology, 2017
The Comprehensive in vitro Proarrhythmia Assay (CiPA) is a global initiative intended to improve drug proarrhythmia risk assessment using a new paradigm of mechanistic assays. Under the CiPA paradigm, the relative risk of drug-induced Torsade de Pointes (
Kelly C. Chang, Sara Dutta, Gary R. Mirams, Kylie A. Beattie, Jiansong Sheng, Phu N. Tran, Min Wu, Wendy W. Wu, Thomas Colatsky, David G. Strauss, Zhihua Li   +10 more
doaj   +5 more sources

Switching treatment to cipaglucosidase alfa plus miglustat positively affects patient-reported outcome measures in patients with late-onset Pompe disease [PDF]

Journal of Patient-Reported Outcomes
Background Late-onset Pompe disease (LOPD), a rare autosomal recessive multisystemic disorder, substantially impacts patients’ day-to-day activities, outcomes, and health-related quality of life (HRQoL).
Priya S. Kishnani, Barry J. Byrne, Kristl G. Claeys, Jordi Díaz-Manera, Mazen M. Dimachkie, Hani Kushlaf, Tahseen Mozaffar, Mark Roberts, Benedikt Schoser, Noemi Hummel, Agnieszka Kopiec, Fred Holdbrook, Simon Shohet, Antonio Toscano, on behalf of the PROPEL Study Group   +14 more
doaj   +2 more sources

Comparing the efficacy of cipaglucosidase alfa plus miglustat with other enzyme replacement therapies for late-onset Pompe disease: a network meta-analysis utilizing patient-level and aggregate data [PDF]

Journal of Comparative Effectiveness Research
Aim: Late-onset Pompe disease is characterized by progressive loss of muscular and respiratory function. Until recently, standard of care was enzyme replacement therapy (ERT) with alglucosidase alfa.
Simon Shohet, Noemi Hummel, Shuai Fu, Ian Keyzor, Alasdair MacCulloch, Neil Johnson, Jeff Castelli, Ilona Czarny-Ozga, Tahseen Mozaffar, Howard Thom   +9 more
doaj   +2 more sources